Article
Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors.
Targeted oncology - 1 Sept 2022
Nishio Makoto, Kato Terufumi, Toyozawa Ryo, Hida Toyoaki
Abstract excerpt
Small molecule mesenchymal-epithelial transition (MET) inhibitors, such as crizotinib, capmatinib, and tepotinib, are treatment options for metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumors have a mutation that leads to MET exon 14 skipping. In clinical trials, these MET inhibitors were associated with a high incidence of peripheral edema, although this was generally mild-to-moderate in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.